About

About cellNUA KSA cellNUA is a biotechnology company transforming how the world approaches infectious disease, immune dysfunction, and cellular regeneration—by unlocking the therapeutic intelligence of nature itself. Founded in Galway, Ireland, with a growing international presence, cellNUA merges evolutionary biology, nanomedicine, and advanced bioinformatics to create naturally inspired, scientifically validated interventions. At its core is a belief that the cell is not a passive victim of disease, but an active architect of its own defense. Our goal is to decode the biochemical logic that governs this cellular resilience and translate it into scalable healthcare platforms. Our flagship platform, BEEMAR™, is the first immune system technology built on comparative glyco-genomics between honeybees and humans. It harnesses the honeybee’s highly evolved immune response—one that is faster than human immunity and uniquely precise—alongside regenerative compounds from marine ecosystems. Through proprietary inoculation and extraction protocols, BEEMAR™ produces pathogen-specific biologics that target viruses, bacteria, and parasites without relying on traditional synthetic drugs. Preclinical trials have shown remarkable reductions in viral load—including against COVID-19, polio, and herpes—and significant inhibition of the malaria parasite, all with no observed cytotoxicity. Supporting platforms like CellMar78™ and Occunase™ extend our approach from therapeutic to preventative medicine. CellMar78™ is a marine-derived, isotonic delivery medium designed for safe gene therapy, stem cell support, and regenerative research. Occunase™, a drug-free nasal spray, forms a mechanical barrier in the nasal mucosa to block respiratory pathogens and allergens—a practical, immune-independent defense for public health. cellNUA’s research is rooted in deep omics analysis, high-throughput screening, and a platform-based architecture that allows rapid adaptation to emerging threats. Our partnerships with institutions such as Johns Hopkins University and Trinity College Dublin, as well as preclinical validations in Europe and Africa, reinforce our commitment to rigorous science and global health equity. With a vision to localize biotech solutions through decentralized “BioCities,” beginning in Europe and the Middle East, we aim to reduce global dependence on imported therapeutics and empower regions with rapid-response health infrastructure. Our work is not only about treatments—it is about restoring trust in biology’s original intelligence and equipping humanity with systems that are proactive, precise, and profoundly sustainable. cellNUA: Where Nature’s Intelligence Becomes the Blueprint for Modern Medicine.